Streptococcus pneumoniae capsular polysaccharide serotype 33F (S. pneumoniae serotype 33F CPS)

Streptococcus pneumoniae serotype 33F capsular polysaccharide is a complex carbohydrate structure that encapsulates the bacterium, acting as its outermost defense layer (PubChem). It serves as a vital virulence factor by inhibiting host complement deposition and preventing opsonophagocytosis by immune cells (PubMed). Serotype 33F has become increasingly prevalent as a cause of invasive pneumococcal disease (IPD), including bacteremia, meningitis, and pneumonia, largely due to serotype replacement following the introduction of narrower-spectrum conjugate vaccines (CDC). As a therapeutic target, this polysaccharide is incorporated into multi-valent vaccines such as the 15-valent pneumococcal conjugate vaccine (PCV15), the 20-valent conjugate vaccine (PCV20), and the 23-valent polysaccharide vaccine (PPSV23) to elicit protective humoral immune responses (FDA). These vaccines stimulate the production of serotype-specific IgG antibodies that recognize the 33F antigen, facilitating bacterial clearance through the recruitment of phagocytes and the activation of the complement system (StatPearls). Clinical monitoring of 33F-specific antibody titers and opsonophagocytic activity is used to assess vaccine efficacy and population-level immunity. Overall, the 33F polysaccharide is a critical component in the global strategy to reduce the burden of pneumococcal disease in both pediatric and adult populations.

Other names

Pneumococcal polysaccharide 33FSerotype 33F capsular antigenStreptococcus pneumoniae serotype 33F capsule33F CPS

Induction of active immunity through the production of serotype-specific opsonophagocytic antibodies that facilitate bacterial clearance